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Foreign H-2-Like Molecules on a Murine Tumor 
(MCG4): Target Antigens for Alloreactive Cytolytic T 
Lymphocytes ( C T L ) and Restricting Elements 
for Virus-Specific C T L 
V. Schirrmacher, F. Garrido, D. Hübsch, E. Garcia-Olivares, and U. Koszinowski 
W E R E C E N T L Y reported about a sarcoma of BALB/c (H-2 d ) mice that 
had been newly induced by methylcholan-
threne and adapted to the ascites form. 1" 3 
This tumor, MCG4, upon transplantation 
into normal BALB/c mice, showed a high 
frequency of spontaneous regression. An H-2 
typing analysis of the tumor revealed a loss of 
four antigenic specificities present on normal 
H-2 d cells (i.e., the private specificity 4 and 
the public specifities 3, 8, and 13) and a gain 
of the public specificity H-2.5, which is char-
acteristic of foreign haplotypes (e.g., H-2 k 
and H-2 b ) . The tumor also reacted with 
different monoclonal BALB/c hybridoma-
derived anti-H-2 k antibodies.3 
Furthermore, regressor animals were found 
to have developed antibodies with high cyto-
toxic antitumor activity. 2 These B A L B / c 
anti-MCG4 isoantisera recognized an alloan-
tigen on the tumor that was very similar to 
H-2 antigens expressed on normal cells from 
mouse strains of foreign H-2 haplotypes. 
Lymphoid cells from strains sharing the H-2 
haplotype with the tumor-bearing host (H-2 d ) 
did not react with the MCG4 isoantisera.2,3 
In this article we will present further 
evidence for the H-2 nature of the alloanti-
gens expressed by the MCG4 tumor. The 
evidence derives from a typing analysis with 
specific cytolytic T lymphocytes (CTL): CTL 
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from B A L B / c mice sensitized against foreign 
H-2 molecules (e.g., H-2 k) wil l be shown to 
react specifically with the MCG4 tumor. 
Furthermore, anti-Sendai virus C T L from 
H-2 k mice will be shown to recognize H -
2k-like determinants as restricting elements 
on Sendai-virus-infected MCG4 tumor target 
cells. 
MATERIALS AND METHODS 
51 Cr Release Cytotoxicity Test 
This 4-hr assay was performed as described pre-
viously.4 
Generation of Cytolytic T Lymphocytes 
C T L against alloantigens were generated in mixed 
lymphoctye cultures in vitro using normal spleen cells as 
responders (R) and mitomycin-C-treated syngeneic or 
allogeneic spleen cells as stimulator cells (S). The cells 
were cocultured for 4-5 days in Falcon flasks at a density 
of 4 x 106 responder cells and 106 stimulator cells per 
milliliter. The effector cells generated were washed twice 
before they were tested in the cytotoxicity assay. Either 
tissue-culture-adapted MCG4 tumor cells or Con-A-
activated lymphoblasts were used as target cells. The 
latter were generated in spleen cell cultures by incubation 
for 2 days with concanavalin A at 12 ß%/vc\\. The blast 
cells were enriched by Ficoll-Isopaque centrifugation and 
labeled with 5 , C r as described.4 
C T L against Sendai virus (SV) were generated by 
coculturing spleen cells from SV-immunized mice in vitro 
with inactivated S V . 5 Target cells were sensitized with 
SV antigens as described.5 
Further details about Materials and Methods are 
published elsewhere.1"3 
RESULTS 
H-2 Allodeterminants on MCG4 
Recognized by Specific Cytolytic T 
Lymphocytes 
Figure 1 illustrates the results obtained in a 
cytotoxicity test using B A L B / c anti-H-2 b 
CTL as effector cells and the BALB/c-
derived tumor MCG4 as target. Specific lysis 
of tumor cells was observed with BALB/c 
32 Transplantation Proceedings, Vol. XII, No. 1 (March), 1980 
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Fig. 1. Allodeterminants recognized on MCG4 by 
BALB/c anti-H-2* cytolytic T lymphoctyes. 
anti-BIO (anti-H-2 b) effector cells, while the 
negative control B A L B / c anti-BlO.D2 was 
noncytotoxic to the tumor. Effector cells with 
selective specificity for the K-end of H-2 b 
[ B A L B / c anti-B10.A(5R)] also lysed the 
MCG4 target, while those with specificity for 
the D-end of H-2 b (BALB/c anti-D2.GD) 
showed little i f any antitumor cytotoxic activ-
ity. Positive control target cells were Con-A 
blasts from BlO.A(5R) and D2.GD (Fig. 1 C 
and D) . These targets were specifically lysed 
by the anti-K b and the anti-D b CTL, respec-
tively, without any detectable cross-reactivity. 
Con-A blasts of BALB/c origin were not 
lysed by any of the B A L B / c anti-H-2 b cyto-
lytic T cells, while they were lysed by 
C57BL/6 ant i -BALB/c (anti-H-2 d) C T L 
(Fig. I B ) . MCG4 was also lysed by the 
anti-H-2 d CTL but to a lower extent than 
observed with the anti-H-2 b CTL. 
Similarly, we tested the expression of H -
2k-like allodeterminants on MCG4 with anti-
H-2 k CTLs (Fig. 2). B A L B / c anti-H-2 k 
CTLs were found to have even higher cyto-
lytic activity on MCG4 targets than the CTLs 
specific for H-2 b (50% 5 1 Cr release at effec-
tontarget cell ratio of 10:1 as compared to 
50:1). Furthermore, CTL with specificity for 
either the K-end or the D-end of the H-2 k 
haplotype was cytolytic towards MCG4, 
while the selective specificity could be demon-
strated on lymphoblast targets expressing the 
K k (Fig. 2B) or the D k (Fig. 2C) molecule. 
H-2-Restricting Determinants on MCG4 
Recognized by Allogeneic Antivirus 
Cytolytic T Lymphocytes 
Anti-Sendai-Virus (SV) CTL were gener-
ated in B10.D2 (H-2 d ) , C57BL/6 (H-2 b ) , and 
M C 0 4 L y s i s by an t i - a Mo C T L 
( a n t i H - 2 M 
E F F E C T O R : T A R G E T C E L L R A T I O 
Fig. 2. Allodeterminants recognized on MCG4 by 
BALB/c anti-H-2k cytolytic T lymphocytes. 
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Fig. 3. H-2Kk-like restricting 
determinants r e c o g n i z e d on 
MCG4 by allogeneic virus-spe-
cific CTL. 
BIO.A (4R) (H-2 h 4 ) mice. They were tested 
for virus-specific cytolytic activity on nonin-
fected and SV-infected MCG4, P815, 
C57BL/6, and BIO.BR lymphoblast target 
cells. The results are illustrated in Fig. 3. 
Anti-SV CTL from H-2 d mice specifically 
lysed the SV-infected H-2 d tumor target P815 
but did not react with any of the other 
virus-infected targets, including MCG4. 
Anti-SV CTL from H-2 b mice specifically 
lysed the SV-infected H-2 b lymphoblast and 
none of the other targets. However, anti-SV 
CTL from BIO.A (4R) mice ( K k D d ) specifi-
cally lysed the SV-infected H-2 k lymphoblast 
from BIO.BR and the SV-infected MCG4 
target. They did not react with P815-SV and 
only marginally with C57BL/6-SV target 
cells. 
These results clearly demonstrate determi-
nants on MCG4 tumor cells that can be 
detected in associative recognition by CTLs 
specific for SV and restricted by molecules 
coded for by the K region of the H-2 k haplo-
type. 
This conclusion was supported by further 
experimental data that are not presented: 
Anti-SV CTL from BIO.BR (H-2 k ) mice 
specifically lysed MCG4-SV and B10.BR-SV 
lymphoblasts but not P815-SV, while anti-SV 
C T L from A . T L ( K s D d ) and D2.GD ( K d D b ) 
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mice lysed specifically P815-SV but not 
MCG4-SV. 
DISCUSSION 
Foreign H-2 specificities have previously 
been detected on various murine tumor cells 
by serologic or transplantation techniques.2,6"9 
According to our present concept about the 
genetic organization of the H-2 complex,1 0"1 2 
such determinants could not be coded for by 
the H-2 alleles of the tumor-bearing host. 
They have therefore been called "alien," "for-
eign," "H-2-like," or "inappropriate." For-
eign H-2 specificities might indicate (1) the 
presence of mutated 1 2 or otherwise altered 
normal H-2 molecules, or (2) the presence of 
products of derepressed normally silent H-2 
genes.13,14 A distinction between these alter-
native hypotheses depends on a detailed 
biologic and chemical characterization of 
these molecules. 
Here we present the first preliminary 
evidence that foreign H-2 specificities can be 
recognized by specific T lymphocytes sensi-
tized against normal H-2 determinants of 
foreign haplotypes. This evidence is twofold: 
(1) H-2 d anti-H-2 k cytotoxic T lymphocytes 
(CTL) specifically lyse the H-2d-derived 
tumor MCG4, and (2) H-2 k anti-Sendai-virus 
(SV) C T L specifically lyse SV-infected 
MCG4 tumor cells and SV-infected target 
cells of H-2 k origin. 
With regard to the first part, namely, the 
typing of MCG4 with alloreactive CTL, the 
data indicate the presence of alloantigenic 
determinants normally expressed on K k , D k 
and K b molecules. BALB/c-derived C T L 
against D b molecules only reacted marginally 
with MCG4. B A L B / c spleen cells cocultured 
with syngeneic H-2 d lymphoid cells did not 
react at all with the tumor under our assay 
conditions, indicating absence of "sponta-
neous" or "natural" antitumor cytolytic activ-
ity. Since anti-K k and anti-D k CTL showed 
only a low degree of cross-reactivity when 
tested on appropriate lymphoblast target 
cells, but reacted strongly with MCG4, it is 
likely that the tumor expresses both a K k -like 
and a D k-like molecule. The reactivity of H-2 d 
anti-K b CTL with the tumor is most easily 
explained as a reactivity against a public 
specificity shared between K k and K b mole-
cules. Such a public specificity has been 
serologically defined as H-2.5. Previous sero-
logic studies have shown that MCG4 indeed 
expresses an H-2.5 determinant.1 , 3 
The data obtained when typing for associa-
tive recognition with H-2-restricted virus-
specific CTL again support our previous 
conclusion that the tumor MCG4 expresses 
H-2 k-like molecules. I t should be mentioned, 
however, that these represent data from one, 
our first, experiment. Unequivocal results 
were obtained in that anti-SV CTL from 
B10.BR ( K k D k ) and B10.A(4R) ( K K D b ) mice 
could lyse SV-infected MCG4 tumor cells, 
while anti-SV C T L from B10.D2 ( K d D d ) , 
A . T L (K S D S ) , D2.GD ( K d D b ) , and C57BL/6 
( K b D b ) mice were negative. These results 
suggest that MCG4 tumor cells express a 
K k-like molecule (possibly also a D k molecule) 
that is recognized as a restrictive element by 
virus-specific CTL. Furthermore, since anti-
H-2 b CTL reacted with the tumor, but H -
2b-derived virus-specified CTL did not, the 
H-2 determinants involved in associative 
recognition appear more restricted to particu-
lar haplotypes than the determinants recog-
nized by alloreactive CTL. Third, as reported 
previously, the MCG4 tumor cells did not 
react in direct cytotoxicity tests with antisera 
against the private specificities 4, 23, and 32, 
which characterize, respectively D d , K k , and 
D k molecules.1 Thus, K k-like molecules were 
detected on MCG4 in associative recognition, 
although they did not seem to carry the 
private specificity 23. This would suggest that 
restricting H-2 determinants recognized by 
specific T cells, although being very distinct, 
are independent of and not identical with the 
private serologic specificities. 
A l l these conclusions, however, have to be 
taken as preliminary, since further experi-
ments are needed to verify and substantiate 
our findings. As it stands at present, the 
MCG4 tumor seems to express predomi-
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nantly an H-2 k-like alloantigen that fulfills 
most criteria of a true foreign H-2 molecule. 
H-2 d-type molecules from the strain of tumor 
origin seem to have a comparatively low 
expression.* Our data are reminiscent of 
Parmiani's BALB/c-derived chemically in-
duced fibrosarcoma C - l , which has been 
characterized as expressing predominantly H -
2d-type molecules, but in addition, alien mole-
cules very similar to K k and D k . 1 5 
* N O T E A D D E D IN PROOF: A possible mix-up of 
the tumor was recently excluded by an isoenzyme analy-
sis performed by Dr. H. -H. Krog, Copenhagen. It 
revealed identity of MCG4 with B A L B / c . 
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Discussion 
Ferrone. Do you have any data from immunodeple-
tion experiments using anti-H-2k or antitumor antisera? 
Did you try any adsorption-inhibition assays in which you 
react H-2 k cells with your antitumor antibodies, then 
determine whether you have blocked adsorption of 
specific H-2 k antiserum? 
Schirrmacher. We have preliminary data from 
sequential immunoprecipitation analysis using isoantise-
rum first, and then anti-H-2d or anti-H-2d first, and then 
isoantiserum that indicates that the foreign H-2 determi-
nants on MCG4 are on molecules different from H-2 d. 
We have not yet done the experiments you suggest. 
Parmiani. The tumor that you described looks very 
similar to the B A L B / c tumor that we use. Could the 
H-2k-like antigen appearing on these B A L B / c tumors be 
due to a common origin for the B A L B / c and C 3 H strains 
of mice? 
Schirrmacher. That is a very interesting point, but I 
don't believe anyone has the answer. 
Alexander. We have always found it very difficult to 
adapt sarcomas to grow in the ascites form. Have you 
tested the original sarcoma for expression of H-2k-like 
antigen? Could the antigen have developed after adapta-
tion of the tumor to the ascites form? 
Schirrmacher. This tumor was induced by Dr. Garri-
do, and had we known it was going to be such an unusual 
tumor, we would have kept the original. Unfortunately, 
we no longer have it. He is setting up an extensive 
tumor-induction program in which the normal tissues of 
the animals will be kept for comparison. It was very 
difficult to get an ascites out of this solid tumor; this was 
the first of about 50 tumors that would grow as an ascites. 
We don't have any idea about the frequency with which 
these inappropriate alloantigens appear or whether they 
are due to adaptation of the cells into an ascites form. Dr. 
Parmiani's C - l tumor is an example of a solid tumor 
expressing alien specificities. 
Bortin. Is the gain or loss of antigenic specificites 
unique to tumor cells maintained in tissue culture or does 
it occur in cells from spontaneous tumors as well? 
Waksal. I would say that 99% of the 30-40 sponta-
neous A K R tumors we have looked at do not express the 
alien H-2.4 specificity. 
Alexander. Dr. Bortin's question is very appropriate. 
How much of this phenomenon is an artifact due to 
carrying the tumors in vitro? About 5 or 6 years ago Dr. 
Festenstein asked for some of our chemically induced 
thymomas. Dr. Garrido examined them and found all 
sorts of specificities; however, when we gave him some 
earlier passage materials, he did not find any of these 
specificites. These alien antigens may not be on sponta-
neous or recently induced tumors. 
Schirrmacher. Dr. Garrido has been looking at 
recently induced tumors, and the situation is just as 
striking as on long-term passage tumors. 
Waksal. Normal fibroblasts passaged in vitro long 
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enough will begin to show antigenic changes similar to 
those seen on tumor cells because of the expression of 
xenotropic MuLV. 
Parmiani. As far as long-term culture of tumors is 
concerned, in our system, not only is the detection of alien 
histocompatibility antigens a problem, there is also a loss 
of original H-2 antigens. 
Bonavida. In our reticulum cell sarcomas we were 
very concerned with whether or not these alien antigens 
were an artifact of culture. We have looked at about 50 
spontaneous tumors, and we still can see the inappro-
priate specificity by immunofluorescence. In addition, 
animals that have the tumor produce antibodies that 
cross-react with the alien specificity. 
